

22 September 2025

ASX ANNOUNCEMENT

Board Chair Transition

Medical Developments International Limited (ASX: MVP) today announced the appointment of Mr Mark Fladrich as Chair of the Board, effective 1 December 2025. Mr Fladrich succeeds Mr Gordon Naylor, who will step down as Chair and resign from the Board on the same date.

Mr Fladrich joined the Board in April 2025 and brings over 30 years of experience in the international pharmaceutical industry. His career includes senior leadership roles at global companies, where he has demonstrated exceptional commercial, strategic, and operational expertise across a broad range of therapeutic areas, including pain management. He currently also serves as Chair of QBiotics, an Australian unlisted public life sciences company focused on oncology and wound healing therapies.

During his executive career, Mr Fladrich was Chief Commercial Officer at Grunenthal, a privately owned German company specialising in pain management. In that role, he led the global commercial organisation, expanded the company's presence into the US, and relaunched a key pain treatment in that market. Prior to joining Grunenthal, Mr Fladrich spent 23 years at AstraZeneca. Mr Fladrich held several senior roles there including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe.

Mr Naylor said, *"Mark brings deep pharmaceutical industry knowledge and proven leadership. MVP's focus on commercial execution in key markets means these attributes are a significant advantage to the Company. Mark's expertise in commercialising pain management treatments has already provided invaluable strategic insight. His governance experience positions him well to lead the Board and support Brent in delivering on our strategic objectives."*

Mr Fladrich said, *"I am honoured to succeed Gordon in this important role. Since his appointment as Chair, the organisation has strengthened governance and remuneration structures, enhanced margins and has developed a clear path forward for sustainably accelerating Pentrox growth. Gordon leaves a resilient organisation poised to continue its growth on a strong foundation. I look forward to working with our very strong Board and Brent to realise the full potential of Pentrox and deliver long-term value for shareholders. I also look forward to working closely with Gordon leading up to 1 December to ensure a seamless transition of responsibilities."*

Mr Naylor has served as a Director and Chair of the Board since October 2020. He currently holds several other governance roles, including Chair of the Board Audit and Risk Committee at Orica Limited and Chair-elect of CSL Seqirus which is anticipated to be demerged from CSL later this financial year.

Mr Fladrich said, *“On behalf of the Board, I extend our sincere appreciation to Gordon for his outstanding service and contribution over the past five years. His financial acumen, strategic insight, and wise counsel have been deeply valued by Directors and Management alike. We thank Gordon for his dedication and wish him continued success in his future endeavours.”*

Mr Naylor remains a shareholder of MVP, holding approximately 1% of MVP’s issued stock.

As part of its governance considerations, the Board has also taken the opportunity to create a Deputy Chair role and has appointed the Chair of Audit and Risk Committee, Mr Paul Townsend, to that position.

Mr Townsend joined the Board in May 2025 and has brought a wealth of knowledge to MVP given his distinguished CFO career spanning multiple sectors. Mr Naylor said, *“Since joining, Paul has brought invaluable experience to the Company given his deep financial acumen and listed company expertise.”*

Mr Naylor said, *“It will be a privilege to present individuals of the calibre of Mark and Paul for election to the Board at MVP’s upcoming Annual General Meeting on Friday, 10 October 2025.”*

~END~

Authorised for release by the Board of Directors.

Enquiries:

Tara Eaton
Company Secretary
+61 (3) 9547 1888

Anita James
Chief Financial Officer
+61 (3) 9547 1888

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & emergency non-opioid pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as change of burns dressings, biopsies and dental procedures, as well as in other medical applications.